MDM2 in breast cancer
- 1 December 1997
- journal article
- symposium ii
- Published by Springer Nature in Breast Cancer
- Vol. 4 (4) , 264-268
- https://doi.org/10.1007/bf02966519
Abstract
The MDM2 protein, an oncogene product, is known to act by suppressing p53 function. Although gene amplification of MDM2 was frequently detected in human sarcomas, it was uncommon in the majority of epithelial tumors including breast cancer. However, recent reports have demonstrated that its translational activity is enhanced in a variety of carcinomas. In this report, we summarized the implications of MDM2 overexpression in human breast cancer from the literature as well as our preliminary results.Keywords
This publication has 24 references indexed in Scilit:
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoproteinNature, 1995
- MDM2 and CDK4 gene amplification in Ewing's sarcomaThe Journal of Pathology, 1995
- mdm2 gene alterations and mdm2 protein expression in breast carcinomasThe Journal of Pathology, 1995
- Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemiaAmerican Journal of Hematology, 1994
- Oncogene Amplification in Urothelial Cancers With p53 Gene Mutation or MDM2 AmplificationJNCI Journal of the National Cancer Institute, 1994
- Altered Patterns of MDM2 and TP53 Expression in Human Bladder CancerJNCI Journal of the National Cancer Institute, 1994
- MDM2 and p53: a Question of BalanceJNCI Journal of the National Cancer Institute, 1994
- MDM2 gene amplification in human breast cancerEuropean Journal Of Cancer, 1994
- The p53-mdm-2 autoregulatory feedback loop.Genes & Development, 1993